News | 11 June 2012
Biodel and Aegis Therapeutics have signed a licensing agreement for ProTek and Intravail technologies for the development and commercialization of glucagon pharmaceutical formulations. According to the agreement, a variety of glucagon presentations ...
Click on the link to read the full article at Pharmaceutical Business Review
(This link will open in a new window)